非小細胞肺がん(NSCLC)治療薬の世界市場:市場、企業、研究開発展望...市場調査レポートについてご紹介

【英文タイトル】Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Non-Small Cell Lung Cancer (NSCLC) Overview
1.2 Why You Should Read this Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to NSCLC and its Treatment
2.1 Lung Cancer is the Most Common Cancer, and NSCLC Accounts for 85%-90% of All Cases
2.2 The Three Main Histological Sub-Types of NSCLC
2.3 Genetic Mutations Allow for Targeted Therapies
2.4 Staging of NSCLC
2.5 Treatment Protocols by Stage
2.5.1 Stage 1 or 2
2.5.2 Stage 3
2.5.3 Stage 4: First Line-Therapy
2.5.3.1 Standard Chemotherapy Used to be the Only Treatment Option
2.5.3.2 Newer Therapies offers Improved Treatment Outcomes
2.5.3.3 Summary of First-Line Therapy Options: Un-Met Need in Squamous Patient Population
2.5.4 Maintenance Therapy
2.5.5 Second-Line and Third-Line Therapy

3. Leading NSCLC Drugs, 2015-2025
3.1 Alimta (pemetrexed) by Eli Lilly – The Leading NSCLC Therapy
3.1.1 Mechanism of Action
3.1.2 Three out of its Four FDA-Approved Indications are for NSCLC
3.1.3 Patent Expiries
3.1.3.1 ‘Method-Of-Use’ Vitamin Dosage Regimen Patent – Alimta’s Saviour from Generic Competition?
3.1.4 NICE Rejects Alimta for Maintenance Therapy
3.1.5 Total Alimta Revenues, 2010-2014
3.1.6 Alimta for NSCLC, 2014
3.1.7 Alimta for NSCLC Forecast, 2015-2025
3.2 Avastin (bevacizumab) – Roche’s Cancer Behemoth is a Leading Presence in NSCLC
3.2.1 Mechanism of Action
3.2.2 Multiple Approved Indications, but NSCLC was one of the First
3.2.3 Growing Discontent with Avastin in NSCLC – Is it Cost-Effective?
3.2.4 Total Avastin Revenues, 2010-2014
3.2.5 Avastin for NSCLC Forecast, 2015-2025
3.3 Tarceva (erlotinib) by Roche
3.3.1 Mechanism of Action
3.3.2 Three of Four Indications are for NSCLC
3.3.3 NICE Changes Mind on Tarceva – and then Changes it Back Again
3.3.4 Total Tarceva Revenues, 2010-2014
3.3.5 Tarceva for NSCLC Forecast, 2015-2025
3.4 Iressa (gefitinib) by AstraZeneca
3.4.1 Iressa Finally Returns to the Crucial US Market after Four Year Departure
3.4.2 Iressa NSCLC Revenues, 2010-2014
3.4.3 Iressa for NSCLC Forecast, 2015-2025
3.5 Gilotrif (afatinib) by Boehringer Ingelheim
3.5.1 Newcomer to the Market Rounds out the Trio of Currently Approved EGFR Inhibitors
3.5.2 Gilotrif Displays Significant Survival Benefit over Tarceva in Squamous Setting
3.5.3 Gilotrif for NSCLC Forecast, 2015-2025
3.6 Xalkori (crizotinib) by Pfizer
3.6.1 Mechanism of Action
3.6.2 The First Approved ALK Inhibitor
3.6.3 Co-Promotion with Merck KGaA, and has Treated Over 8,000 Patients
3.6.4 Xalkori NSCLC Revenues, 2012-2014
3.6.5 Xalkori for NSCLC Forecast, 2015-2025
3.7 Abraxane (paclitaxel Protein-Bound) by Celgene
3.7.1 Mechanism of Action
3.7.2 Relatively Recent Approval for NSCLC Indication
3.7.3 Finally Approved for NSCLC in the EU
3.7.4 Total Abraxane Revenues, 2010-2014
3.7.5 Abraxane for NSCLC Forecast, 2015-2025
3.8 Taxotere (docetaxel) by Sanofi
3.8.1 Mechanism of Action and Approved Indications
3.8.2 Sanofi Unable to Prevent Generics, Despite Appeal
3.8.3 Total Taxotere Revenues, 2010-2014
3.8.4 Taxotere for NSCLC Forecast, 2015-2025
3.9 Cyramza (ramucirumab) by Eli Lilly
3.9.1 Mechanism of Action
3.9.2 Many Approvals in Quick Succession
3.9.3 Cyramza for NSCLC Forecast, 2015-2025
3.10 Gemzar (gemcitabine) by Eli Lilly
3.11 Zykadia (ceritinib) by Novartis
3.11.1 Mechanism of Action and Recent Approval
3.11.2 Zykadia for NSCLC Forecast, 2015-2025
3.12 Opdivo (nivolumab) by Bristol-Myers Squibb
3.12.1 Mechanism of Action – Works With the Immune System to Fight Cancers
3.12.2 Swift Approvals through FDA Priority Review Programmes
3.12.3 Good News and Bad News for NSCLC from CheckMate Trials
3.12.4 Opdivo for NSCLC Forecast, 2015-2025

4. NSCLC R&D Pipeline, 2015-2025
4.1 Alecensa (alectinib) by Roche
4.1.1 Japan Becomes First Country to Approve and Launch Alectinib
4.1.2 Roche is Inching Closer Towards the All-Important US Approval
4.1.3 Four Ongoing Clinical Trials involving Alectinib in NSCLC
4.1.4 Japanese Revenues and Future Outlook
4.2 Vargatef (nintedanib) by Boehringer Ingelheim
4.2.1 EU Becomes First Region to Approve Vargatef
4.2.2 NICE has a Change of Heart on Vargatef
4.2.3 Ongoing Clinical Trials Involving Vargatef in NSCLC
4.3 AZD9291 by AstraZeneca
4.3.1 Regulatory Filings in the US and EU, Expected Times for Filings in Japan and China
4.3.2 Collaboration with Roche to Develop Companion Diagnostic
4.3.3 Positive Preliminary Results Presented at ASCO 2015
4.3.4 Ongoing Clinical Trials Involving AZD9291 in NSCLC
4.4 Rociletinib (CO-1686) by Clovis Oncology
4.4.1 In a Race to Approval Against AZD9291
4.4.2 Results So Far Have not Distinguished it Enough from Main Rival
4.4.3 Four Ongoing Clinical Trials Involving Rociletinib in NSCLC
4.5 Keytruda (pembrolizumab) by Merck (MSD)
4.5.1 Has Been Approved for Melanoma, NSCLC is one of the Next Major Targets
4.5.2 Ongoing Clinical Trials Involving Keytruda in NSCLC
4.6 Ganetespib (STA-9090) by Synta Pharmaceuticals
4.6.1 Ganetespib Mechanism of Action
4.6.2 Three Ongoing Clinical Trials Involving Ganetespib in NSCLC
4.7 Halaven (eribulin) by Eisai
4.7.1 Halaven Mechanism of Action
4.7.2 Clinical Trials Involving Halaven in NSCLC
4.8 Necitumumab by Eli Lilly
4.8.1 Phase 3 Results Show Modest Benefits and Worrying Adverse Event Profile
4.8.2 Eli Lilly has Filed for Approval in US and EU, and Verdict is Likely to be Positive, Despite Reservations
4.8.3 Ongoing Clinical Trials Involving Necitumumab in NSCLC
4.9 Atezolizumab (MPDL3280A) by Roche
4.9.1 Mechanism of Action
4.9.2 Atezolizumab Doubles Likelihood of Survival in Certain Subset of Patients
4.9.3 Six Ongoing Clinical Trials Involving Atezolizumab in NSCLC

5. Global NSCLC Market, 2015-2025
5.1 The Global NSCLC Market Forecast, 2015-2025
5.2 What Factors will Drive Growth in the Global NSCLC Market?
5.3 Growing Ageing Population
5.4 The Identification of Biomarkers for Targeted Therapies
5.5 Dynamic and Lucrative Sector with Strong Pipeline
5.6 Satisfying the Large Un-Met Need that is Treatment for Squamous Patients
5.7 What Factors will Restrain Growth in the Global NSCLC Market?
5.8 Patent Expiries and Generic Erosion will be the Main Detriment to the Market
5.9 New Therapies That Reportedly Offer Only Modest Benefits Over Existing Treatments
5.10 Declining Healthcare Budgets lead to Cost Pressures, and Resistance to Therapies is another Issue
5.11 SWOT Analysis of the Global NSCLC Market

6. Leading Therapeutic Segments and National Markets within the Global NSCLC Market
6.1 Therapeutic Composition of the Market in 2015 Compared to 2025
6.1.1 Therapeutic Segments Forecast, 2015-2025
6.1.2 Chemotherapy Segment Forecast, 2015-2025
6.1.3 EGFR and ALK Inhibitors Segment Forecast, 2015-2025
6.1.4 VEGF / VEGFR Inhibitors Segment Forecast, 2015-2025
6.1.5 Immunotherapy Segment Forecast, 2015-2025
6.2 Leading National Markets for NSCLC
6.2.1 Regional Composition of the Global Market in 2015, Compared to 2025
6.2.2 Leading Regional Markets for NSCLC Forecast, 2015-2025
6.2.3 US NSCLC Market, 2015-2025
6.2.3.1 Experiencing Some Changes, but Will Retain Dominance Throughout Forecast Period
6.2.3.2 US NSCLC Market Forecast, 2015-2025
6.2.4 EU5 NSCLC Market, 2015-2025
6.2.4.1 German NSCLC Market: Leader in EU, but Facing Big Reforms
6.2.4.2 German NSCLC Market Forecast, 2015-2025
6.2.4.3 French NSCLC Market: Strong National Healthcare System, Despite Economic Woes
6.2.4.4 French NSCLC Market Forecast, 2015-2025
6.2.4.5 Italian NSCLC Market
6.2.4.6 Italian NSCLC Market Forecast, 2015-2025
6.2.4.7 UK NSCLC Market: Pricing is a Key Issue, Providing Restraints to Revenues
6.2.4.8 UK NSCLC Market Forecast, 2015-2025
6.2.4.9 Spanish NSCLC Market
6.2.4.10 Spanish NSCLC Market Forecast, 2015-2025
6.2.5 Japanese NSCLC Market
6.2.5.1 Expansion of the Generics Market is a Key Factor
6.2.5.2 Japanese NSCLC Market Forecast, 2015-2025
6.2.6 BRIC NSCLC Market, 2015-2025
6.2.6.1 China NSCLC Market: Rapid Growth Will Make it one of the Major Global Players
6.2.6.2 China NSCLC Market Forecast, 2015-2025
6.2.6.3 Brazilian NSCLC Market: Taken Great Strides Forward with Healthcare
6.2.6.4 Brazilian NSCLC Market Forecast, 2015-2025
6.2.6.5 Russian NSCLC Market: Punches Below its Weight
6.2.6.6 Russian NSCLC Market Forecast, 2015-2025
6.2.6.7 Indian NSCLC Market: Generics are King
6.2.6.8 Indian NSCLC Market Forecast, 2015-2025

7. Research Interview
7.1 Interview with Novartis
7.1.1 On the Need for More than one ALK Inhibitor on the Market
7.1.2 Main Trends and Opportunities for NSCLC
7.1.3 The Present and the Future

8. Conclusions from Our Research and Analysis
8.1 How Will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How Will the National Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks


【レポート販売概要】

■ タイトル:非小細胞肺がん(NSCLC)治療薬の世界市場:市場、企業、研究開発展望
■ 英文:Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025
■ 発行日:2015年10月
■ 調査会社:visiongain
■ 商品コード:VGAIN5112511
■ 調査対象地域:グローバル
  • 折りたたみ箱の世界市場2016-2020
    About Folding Carton Folding cartons are paperboards that are cut, folded, laminated, and printed for packaging goods. They are available in various sizes and shapes and are often delivered as flat paperboards marked with folding lines to help in packaging. These cartons are made of virgin wood pulp, recycled paper stock, or other fibers. There are new technologies that give folding cartons aaesth …
  • 世界の小型自動車用ターボチャージャー市場【2015年1月更新版】
    This latest just-auto report edition offers a global review of the OE turbochargers sector, its suppliers, top markets, technologies and market forecasts. This global market study offers: Automotive OE turbochargers market size estimates Latest technologies and trends Market share data tables Exclusive interviews with major companies Profiles of the major players including their strategies and pro …
  • InterOil Corporation:石油・ガスバリューチェーン分析レポート2013
    InterOil Corporation Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "InterOil Corporation" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “InterOil Corporation”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report exam …
  • 頸動脈ステントの世界市場2015-2019
    About Carotid Stent Carotid artery disease refers to the blockage or narrowing of carotid arteries due to plaque formation (Fibrous tissue, cholesterol, and calcium deposits. The carotid arteries are present in the neck and supply blood to the brain. Carotid artery stenting is a minimally invasive surgical procedure used to treat carotid artery disease. The technique involves the insertion of a sl …
  • 世界のフェノキシエタノール防腐剤市場2015
    The Global Phenoxyethanol Preservatives Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Phenoxyethanol Preservatives industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Phenoxyethanol Preservatives market analysis is provided for the international m …
  • 南米の工業用遠心分離機市場分析・予測
    Based on product type, the South America Industrial Centrifuge Market is projected to grow at a CAGR of 5.2% from 2016 to 2021. Increasing demand from process industries is one of the major drivers in the South American Industrial Centrifugation market. The demand for centrifuges is growing in various process industries primarily due to factors such as increasing population, growing urbanization i …
  • インダクタの世界市場:固定インダクタ、可変インダクタ、結合インダクタ、多層インダクタ、パワーインダクタ、面実装インダクタ
    The global inductor market is estimated at USD 3.05 Billion in 2015 and is expected to reach USD 3.98 Billion by 2020, at a CAGR of 5.5% from 2015 to 2020. Inductors are used in consumer electronics, such as smartphones, tablets, notebooks, desktop computers, servers, Blu-ray recorders, set-top boxes, portable gaming devices, and GPS products. These products are extremely popular and are being ado …
  • 車線逸脱警報システム(LDWS)の世界市場2016-2020
    About Lane Departure Warning Systems (LDWSs) LDWS are designed to help drivers reduce the number of unintended lane departures. Such systems help drivers to focus on driving and avoid accidents that may result from lack of attention or drowsiness. Many single vehicle departure crashes take place in light traffic situations and good weather conditions. LDWS warn drivers every time they unintentiona …
  • 世界の排気センサ市場2015
    The Global Exhaust Sensor Industry Report 2015 is a professional and in-depth study on the current state of the Exhaust Sensor industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Exhaust Sensor market analysis is provided for the international markets including development trends, competitive landscape …
  • 再発性悪性神経膠腫(Recurrent Malignant Glioma):世界の治験レビュー(2015年上半期版)
    Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the t …
  • Home Automation: Solutions and Suppliers 2010
    Home Automation is the automatic control of a home's electronic systems, such as security, heating and air conditioning, entertainment, and lighting. A home automation system is one in which these systems are integrated into one, easy-to-use system. The purpose of a home automation system is to enable residents to perform normal daily tasks in a simpler manner. A home automation system will use sc …
  • 産業用ロボットの世界市場:関節ロボット、直角座標ロボット、SCARAロボット、円筒座標ロボット、パラレルロボット
    The global industrial robotics market is expected to reach USD 79.58 Billion by 2022, growing at a CAGR of 11.92% between 2016 and 2022. The main drivers of this growth are the adoption of automation to ensure quality production and meet market demand as well as the growing demand from small- and medium-scale enterprises in developing countries. The maximum growth for industrial robotics is expect …
  • プラストマーの世界市場予測(~2020)
    The market size of plastomers is estimated to reach USD 5.33 Billion by 2020, registering a CAGR of 7.4% between 2015 and 2020. The plastomer market is driven by its unique blend of properties of both, elastomers and plastics. Plastomers have narrow molecular weight distribution that differentiates them from regular plastics or elastomers for which they offer excellent sealing properties and are t …
  • テレビ広告支出の世界市場2015-2019
    About TV Ad Spending TV advertising enables advertisers to create awareness about their products and influence the buying decision of consumers. Since TV is the most widely viewed medium worldwide, advertisers are drawn to this medium of advertising. Advertising on TV can be done using traditional commercial channels or multichannel campaigns. Advertisers have increased their spending on TV advert …
  • 転売チケットの世界市場:コンサートチケット、映画チケット、スポーツチケット
    The global market for secondary tickets is expected to exhibit significant growth during the forecast period and is positively affected by the recent increase in the number of sporting and live events. This recent rise in the number of sporting and live events is envisaged to result in this market’s remarkable CAGR of more than 19% by 2020. Technavio market research analysts estimate eminent facto …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。